Godavari Drugs Ltd. (BSE: 530317) is a Secunderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹119 Cr, it ranks #3,106 by market cap among the 6,197 Indian listed companies on FinBizNet, and #67 of 86 in Medicinal Chemicals and Botanical Products. At ₹122.00 (as of 16 Nov 2026), the share price is 15.5% below its 52-week high of ₹144.35 and 75.0% above its 52-week low of ₹69.70. The share price is up 45.9% over one year and up 22.0% over three months.
| Current Price | ₹122.00 |
|---|---|
| Market Cap | ₹119 Cr |
| BSE Code | 530317 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 21.8 |
| Return on Equity | 6.87% |
| Return on Assets | 3.10% |
| 52-Week Range | ₹69.70 – ₹144.35 |
| 1-Year Price Change | +45.9% |
| 3-Month Price Change | +22.0% |
| Beta (1Y) | 0.47 |
| Headquarters | Secunderabad, Telangana |
| Website | godavaridrugs.com |
| Revenue | ₹28 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 4.0% |
| EPS (Basic) | ₹1.10 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Godavari Drugs Ltd. reported revenue of ₹28 Cr in Q1 FY27, up 17.4% from ₹24 Cr in Q1 FY26 and down 15.7% from ₹33 Cr in Q4 FY26. It posted a net profit of ₹1 Cr for the quarter, against a net profit of ₹1 Cr in Q1 FY26 (up 6.7%). Across the 8 quarters from Q2 FY25 to Q1 FY27, quarterly revenue ranged from ₹22 Cr (Q3 FY26) to ₹33 Cr (Q4 FY26). The company was profitable in each of these 8 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹28 Cr | ₹1 Cr | 4.0% |
| Q4 FY26 | ₹33 Cr | ₹1 Cr | 3.9% |
| Q3 FY26 | ₹22 Cr | ₹1 Cr | 3.4% |
| Q2 FY26 | ₹27 Cr | ₹1 Cr | 3.8% |
| Q1 FY26 | ₹24 Cr | ₹1 Cr | 4.4% |
| Q4 FY25 | ₹26 Cr | ₹1 Cr | 3.5% |
| Q3 FY25 | ₹30 Cr | ₹1 Cr | 2.6% |
| Q2 FY25 | ₹26 Cr | ₹1 Cr | 4.2% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 63.31% of Godavari Drugs Ltd.'s shares as of Mar 2026, unchanged from Mar 2025. Delivery averaged 89.5% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Godavari Drugs Limited manufactures and sells active pharmaceutical ingredients (APIs), drug intermediaries, and fine chemicals in India. The company offers APIs, including ciprofloxacin HCl, ciprofloxacin lactate, ciprofloxacin betaine, mefenamic acid, enrofloxacin, and elthambutoal HCI; and intermediaries, such as A D lactone for spironolactone and 6 mercaptopurine for azathioprine. It also provides loan licenses and contract manufacturing services for APIs and drug intermediates. The company serves the life science industry. Godavari Drugs Limited was incorporated in 1987 and is based in Secunderabad, India.
1. Pharmaceuticals-This segment manufactures active pharmaceutical ingredients and its intermediates.
1. Manufacture and Sale of Active Pharmaceutical Ingredients (API) and its intermediates-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Godavari Drugs Ltd. | ₹119 Cr | 21.8 | 6.87% | ₹28 Cr | +45.9% |
Listed by market capitalisation. Ratios are shown for context only.
Godavari Drugs Ltd. is trading at ₹122.00, with a market capitalisation of ₹119 Cr.
Godavari Drugs Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Godavari Drugs Ltd. has a P/E of 21.8 and a return on equity of 6.87%.
Godavari Drugs Ltd. is listed on the BSE under the scrip code 530317.
Godavari Drugs Ltd.'s share price is up 45.9% over one year and up 22.0% over three months. Its 52-week range is ₹69.70 to ₹144.35.
In Q1 FY27, Godavari Drugs Ltd. reported revenue of ₹28 Cr and net profit of ₹1 Cr, with basic EPS of ₹1.1 (standalone, parsed from the company's exchange filing).
Godavari Drugs Ltd. reported revenue of ₹28 Cr in Q1 FY27, up 17.4% from ₹24 Cr in Q1 FY26 and down 15.7% from ₹33 Cr in Q4 FY26.
Promoters held 63.31% of Godavari Drugs Ltd.'s shares as of Mar 2026, unchanged from Mar 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.